{
    "2018-04-18": [
        [
            {
                "time": "2018-04-19",
                "original_text": "Pre-Market Earnings Report for April 19, 2018: PM, DHR, BK, TSM, BBT, PPG, NVS, BX, NUE, KEY, GWW, DGX",
                "features": {
                    "keywords": [
                        "Earnings",
                        "Pre-Market",
                        "NVS"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-17",
                "original_text": "Analysts’ Recommendations for Novartis on April 17",
                "features": {
                    "keywords": [
                        "Analysts",
                        "Recommendations",
                        "Novartis"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-17",
                "original_text": "Amgen's Aimovig Reduces Episodic Migraine in 30% Patients",
                "features": {
                    "keywords": [
                        "Amgen",
                        "Aimovig",
                        "Migraine"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-17",
                "original_text": "Roche Hemophilia Drug Gets Breakthrough Therapy Designation",
                "features": {
                    "keywords": [
                        "Roche",
                        "Hemophilia",
                        "Drug",
                        "Breakthrough",
                        "Therapy"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-17",
                "original_text": "Sandoz Signs Deal With Pear Therapeutics",
                "features": {
                    "keywords": [
                        "Sandoz",
                        "Deal",
                        "Pear",
                        "Therapeutics"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-17",
                "original_text": "Jazz Pharmaceuticals’ Xyrem, Erwinase, and Defitelio",
                "features": {
                    "keywords": [
                        "Jazz",
                        "Pharmaceuticals",
                        "Xyrem",
                        "Erwinase",
                        "Defitelio"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-17",
                "original_text": "How Exelixis’s Cabomeytx and Cometriq Performed in 4Q17 and 2017",
                "features": {
                    "keywords": [
                        "Exelixis",
                        "Cabomeytx",
                        "Cometriq",
                        "4Q17",
                        "2017"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-17",
                "original_text": "Major Averages Close Mixed Following Lackluster Session - U.S. Commentary",
                "features": {
                    "keywords": [
                        "Major",
                        "Averages",
                        "Close",
                        "Mixed",
                        "Lackluster",
                        "Session"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "market"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-04-17",
                "original_text": "The Swiss Stock Market Inched Higher As Investors Pause",
                "features": {
                    "keywords": [
                        "Swiss",
                        "Stock",
                        "Market",
                        "Inched",
                        "Higher",
                        "Investors",
                        "Pause"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "market"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-17",
                "original_text": "Novartis’s 1Q18 Estimates: Expectations for Alcon",
                "features": {
                    "keywords": [
                        "Novartis",
                        "1Q18",
                        "Estimates",
                        "Alcon"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-17",
                "original_text": "Novartis’s 1Q18 Estimates: Expectations for Sandoz",
                "features": {
                    "keywords": [
                        "Novartis",
                        "1Q18",
                        "Estimates",
                        "Sandoz"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}